Comparison · NCT02940860-6ef11fec
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8. Trial comparisons, record NCT02940860-6ef11fec. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02940860-6ef11fec
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0317 | 0.0225 | 0.0443 | wilson | |
| Risk in group 2 | 0.008 | 0.00312 | 0.0204 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0237 | 0.00826 | 0.0372 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.96 | 1.41 | 11.1 | log | |
| Odds ratio, group 1 over group 2 | 4.05 | 1.43 | 11.5 | log | |
| Number needed to treat, for one more participant with the outcome on Iron Isomaltoside/Ferric Derisomaltose than on Iron Sucrose | 42.3 | 26.8 | 121 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | 32 | 1,011 | OG000 |
| Group 2 | Iron Sucrose | Iron sucrose, administered IV | 4 | 500 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8
- Description
- Safety~Results show the number of participants who had s-phosphate \<2 mg/dL at any time from baseline to week 1, 2, 4, or 8.
- Time frame
- Baseline, week 1, 2, 4, and 8
- Population
- Safety analysis set. All randomised subjects who received at least one dose of the investigational product.
Source ClinicalTrials.gov
Trial
- Title
- Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
- NCT number
- NCT02940860
- Phases
- PHASE3
- Conditions
- Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
- Interventions
- Iron isomaltoside/ferric derisomaltose, Iron sucrose
- Lead sponsor
- Pharmacosmos A/S
- Results first posted
- 2020-03-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02940860?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02940860-6ef11fec